vs
AVANOS MEDICAL, INC.（AVNS）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是Resolute Holdings Management, Inc.的1.5倍（$180.9M vs $117.7M），AVANOS MEDICAL, INC.净利率更高（-0.7% vs -1.5%，领先0.7%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $21.3M）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
AVNS vs RHLD — 直观对比
营收规模更大
AVNS
是对方的1.5倍
$117.7M
净利率更高
AVNS
高出0.7%
-1.5%
自由现金流更多
RHLD
多$167.9M
$21.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $117.7M |
| 净利润 | $-1.3M | $-1.7M |
| 毛利率 | 47.5% | 55.7% |
| 营业利润率 | 1.4% | 30.2% |
| 净利率 | -0.7% | -1.5% |
| 营收同比 | 0.7% | — |
| 净利润同比 | 99.7% | — |
| 每股收益（稀释后） | $-0.02 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSRHLD
| Q4 25 | $180.9M | $117.7M | ||
| Q3 25 | $177.8M | $120.9M | ||
| Q2 25 | $175.0M | $119.6M | ||
| Q1 25 | $167.5M | $103.9M | ||
| Q4 24 | $179.6M | — | ||
| Q3 24 | $170.4M | — | ||
| Q2 24 | $171.7M | — | ||
| Q1 24 | $166.1M | — |
净利润AVNSRHLD
| Q4 25 | $-1.3M | $-1.7M | ||
| Q3 25 | $-1.4M | $-231.0K | ||
| Q2 25 | $-76.8M | $-611.0K | ||
| Q1 25 | $6.6M | $-3.4M | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | — | ||
| Q2 24 | $1.8M | — | ||
| Q1 24 | $-900.0K | — |
毛利率AVNSRHLD
| Q4 25 | 47.5% | 55.7% | ||
| Q3 25 | 48.4% | 59.0% | ||
| Q2 25 | 52.6% | 57.5% | ||
| Q1 25 | 53.6% | 52.5% | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
营业利润率AVNSRHLD
| Q4 25 | 1.4% | 30.2% | ||
| Q3 25 | 0.1% | 34.3% | ||
| Q2 25 | -42.6% | 34.0% | ||
| Q1 25 | 6.1% | 24.7% | ||
| Q4 24 | -233.0% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 2.4% | — |
净利率AVNSRHLD
| Q4 25 | -0.7% | -1.5% | ||
| Q3 25 | -0.8% | -0.2% | ||
| Q2 25 | -43.9% | -0.5% | ||
| Q1 25 | 3.9% | -3.2% | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | -0.5% | — |
每股收益（稀释后）AVNSRHLD
| Q4 25 | $-0.02 | $-0.20 | ||
| Q3 25 | $-0.03 | $-0.03 | ||
| Q2 25 | $-1.66 | $-0.07 | ||
| Q1 25 | $0.14 | $-0.39 | ||
| Q4 24 | $-8.64 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.04 | — | ||
| Q1 24 | $-0.02 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $205.5M |
| 总债务越低越好 | $90.3M | $169.8M |
| 股东权益账面价值 | $778.2M | $6.5M |
| 总资产 | $1.1B | $333.4M |
| 负债/权益比越低杠杆越低 | 0.12× | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资AVNSRHLD
| Q4 25 | $89.8M | $205.5M | ||
| Q3 25 | $70.5M | $148.0M | ||
| Q2 25 | $90.3M | $99.9M | ||
| Q1 25 | $97.0M | $71.0M | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
总债务AVNSRHLD
| Q4 25 | $90.3M | $169.8M | ||
| Q3 25 | $93.4M | $173.4M | ||
| Q2 25 | $95.7M | $177.1M | ||
| Q1 25 | $98.0M | $180.7M | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSRHLD
| Q4 25 | $778.2M | $6.5M | ||
| Q3 25 | $778.0M | $10.8M | ||
| Q2 25 | $776.3M | $9.6M | ||
| Q1 25 | $839.4M | $8.9M | ||
| Q4 24 | $828.5M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
总资产AVNSRHLD
| Q4 25 | $1.1B | $333.4M | ||
| Q3 25 | $1.1B | $293.2M | ||
| Q2 25 | $1.0B | $253.3M | ||
| Q1 25 | $1.1B | $214.3M | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.7B | — |
负债/权益比AVNSRHLD
| Q4 25 | 0.12× | 26.03× | ||
| Q3 25 | 0.12× | 16.01× | ||
| Q2 25 | 0.12× | 18.42× | ||
| Q1 25 | 0.12× | 20.38× | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $189.2M |
| 自由现金流率自由现金流/营收 | 11.8% | 160.8% |
| 资本支出强度资本支出/营收 | 3.8% | 5.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | $313.2M |
8季度趋势，按日历期对齐
经营现金流AVNSRHLD
| Q4 25 | $28.2M | $196.1M | ||
| Q3 25 | $14.0M | $59.6M | ||
| Q2 25 | $6.8M | $48.9M | ||
| Q1 25 | $25.7M | $18.4M | ||
| Q4 24 | $57.9M | — | ||
| Q3 24 | $23.0M | — | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $-8.0M | — |
自由现金流AVNSRHLD
| Q4 25 | $21.3M | $189.2M | ||
| Q3 25 | $7.0M | $58.6M | ||
| Q2 25 | $-4.2M | $47.5M | ||
| Q1 25 | $19.0M | $17.8M | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $-12.1M | — |
自由现金流率AVNSRHLD
| Q4 25 | 11.8% | 160.8% | ||
| Q3 25 | 3.9% | 48.5% | ||
| Q2 25 | -2.4% | 39.7% | ||
| Q1 25 | 11.3% | 17.1% | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | -7.3% | — |
资本支出强度AVNSRHLD
| Q4 25 | 3.8% | 5.8% | ||
| Q3 25 | 3.9% | 0.8% | ||
| Q2 25 | 6.3% | 1.2% | ||
| Q1 25 | 4.0% | 0.6% | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 2.5% | — |
现金转化率AVNSRHLD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RHLD
暂无分部数据
